Fairman Group’s Definium Therapeutics DFTX Stock Holding History

Fairman Group’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-85	Closed	-$799	–	411
2024 Q1	$799	Hold	85	–	–	﹤0.01%	335
2023 Q4	$311	Buy	+85	New	+$256	﹤0.01%	364

Other funds holding DFTX

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fairman Group's DFTX Position: Q2 2024 in Review

Fairman Group sold out of Definium Therapeutics (DFTX) in Q2 2024, closing a stake of 85 shares — an estimated $799 sold.

Fairman Group first reported a position in DFTX in Q4 2023 and held it in 2 quarters. The position peaked at $799 in Q1 2024. 151 funds tracked by Wall St. Rank hold DFTX as of Q2 2024.

Fairman Group reported no remaining Definium Therapeutics position as of Q2 2024 after selling out during the quarter.
Fairman Group sold 85 Definium Therapeutics shares in Q2 2024, an estimated $799.
Fairman Group first reported a position in Definium Therapeutics in Q4 2023 and held it in 2 quarters.
Fairman Group's Definium Therapeutics position peaked at $799 in Q1 2024.
151 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2024.

Based on Fairman Group's 13F filing for Q2 2024, filed 29 Jul 2024.